A rapid diagnostic test that allows doctors to target the right drug for the right patient immediately could save money by reducing the length of stay in a hospital for these patients. Identifying patients with a drug-resistant infection quickly also prevents their infection from being passed on to patients around them because they can be rapidly isolated and infection control measures can be put in place."
The Review on Antimicrobial Resistance, Chaired by Jim O’Neill. October 2015
- Carbapenem resistance results in increased mortality in hospitalized patients and is associated with higher total hospital costs.1
- Organisms carrying integron and plasmid-encoded carbapenemase enzymes are largely responsible for the rapid spread of carbapenem resistance.2
- CDC recommends comprehensive infection control measures for patients who are colonized or infected with carbapenemase-producing organisms.3
- Current test methods lack the sensitivity, ease of use, and rapid results required to respond quickly to the threat of carbapenemase-producing organisms.
(1) Judd WR, et al. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients. American Journal of Infection Control. June 2016. (http://www.sciencedirect.com/science/article/pii/S0196655316303431); (2) https://wwwnc.cdc.gov/eid/article/17/10/pdfs/11-0655.pdf; (3) http://www.cdc.gov/hai/pdfs/cre/CRE-guidance-508.pdf
Xpert® Carba-R can detect and differentiate the most prevalent carbapenemase gene families in just 48 minutes.
- Screening* high-risk patients with Xpert Carba-R can alert clinicians and infection preventionists (IPs) rapidly of the presence of gene sequences associated with carbapenem non-susceptibility in gram-negative bacteria, including Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter species.
- Rapid detection and differentiation of the blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP gene sequences helps clinicians and IPs to optimize patient management.
- Comprehensive infection control measures should be applied to patients who are colonized or infected with carbapenemase-producing organisms.3
* The CDC recommendations use the term screening synonymously with assessing colonization status. Xpert Carba-R is not indicated for screening. See Product Insert for complete details.
- Cepheid - The Molecular Diagnostics Leader
- Dr. Stan Deresinski: CRE & MDR Acinetobacter
- Dr. Fred Tenover: Carbapenem Resistance: A Medical and Public Health Challenge
- Catalog #: GXCARBAR-10
Number of Tests: 10
- How can I place an order?
Submit your request using our Request Information form, or call 1.888.838.3222, select option 1.